Specialists have reported the successful first-line use of autologous hematopoietic stem cell transplantation (AHSCT) to reduce disability in patients with highly active “aggressive” RRMS.
Dr Joyutpal Das from Sheffield Teaching Hospitals NHS Foundation Trust, in Sheffield, UK, told the ECTRIMS audience of the results of a study assessing the safety and efficacy of AHSCT as a first-line disease-modifying therapy in patients with aggressive RRMS.